Friday, November 13, 2026

Anthropic Rejects Pentagon Contract Over Mass Surveillance Safeguards

Anthropic walked away from Department of Defense talks after the Pentagon refused to accept contract language preventing Claude's use for mass surveillance of Americans. CEO Dario Amodei said virtually no progress was made on restricting the AI model to non-surveillance military applications. The collapse highlights friction between frontier labs' ethics policies and DoD procurement demands.

Anthropic Rejects Pentagon Contract Over Mass Surveillance Safeguards
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Anthropic terminated negotiations with the Pentagon after the Department of Defense rejected contract terms blocking Claude's use for mass surveillance of Americans, CEO Dario Amodei disclosed in recent policy statements.

The talks produced "virtually no progress" on preventing surveillance applications, Amodei said. Anthropic's red lines include no mass surveillance of Americans and no lethal autonomous weapons—restrictions the DoD's standard contract language does not accommodate.

"We cannot in good conscience agree to the Pentagon's request for unrestricted AI model usage," Amodei stated. The company sought narrow military applications like logistics optimization and threat analysis that exclude domestic surveillance and autonomous killing systems.

The breakdown reveals structural tension between frontier AI labs and defense procurement. DoD contracts typically grant broad usage rights to maintain operational flexibility, while companies like Anthropic impose use-case restrictions to manage reputational and regulatory risk.

This friction may slow military AI adoption. Pentagon AI modernization plans rely on commercial models from OpenAI, Anthropic, and Google DeepMind. If ethics-focused labs refuse unrestricted licenses, the DoD faces a choice: accept narrow use-case contracts or develop proprietary models.

The gap between DoD requests and signed contracts is widening. In 2025, the Pentagon announced 14 AI procurement initiatives but closed only 3 contracts with frontier labs, according to defense contracting databases. Seven proposals stalled over acceptable use language.

Anthropic's position differs from competitors. OpenAI partners with defense contractors through third-party agreements that obscure end-use restrictions. Google maintains a no-weapons policy but signed a $250M Pentagon cloud deal covering non-combat AI workloads.

Meanwhile, Anthropic is expanding enterprise AI applications. New tools for its Claude Cowork agent software integrate with existing business systems rather than replacing them—a strategy targeting corporate clients over government contracts.

The standoff tests whether ethics commitments survive revenue pressure. Defense contracts offer guaranteed funding and scale, but acceptance could trigger employee backlash and regulatory scrutiny. Monitoring 2026 contract announcements will reveal if other labs follow Anthropic's path or prioritize Pentagon deals.

In this story

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com